PURE FILAMENTOUS BACTERIOPHAGE AND METHODS OF PRODUCING SAME

1 . A pharmaceutical composition comprising wild-type filamentous bacteriophage or filamentous bacteriophage which does not display an antibody or a non-filamentous bacteriophage antigen on its surface, said composition comprising less than 1×10 −10 endotoxin units per filamentous bacteriophage; and a pharmaceutically acceptable carrier.

2 . The pharmaceutical composition of claim 1 , comprising less than 1×10 −11 endotoxin units per filamentous bacteriophage.

3 . The pharmaceutical composition of claim 1 , comprising less than 1×10 −12 endotoxin units per filamentous bacteriophage.

4 . The pharmaceutical composition of claim 1 , comprising less than 1×10 −13 endotoxin units per filamentous bacteriophage.

5 . The pharmaceutical composition of claim 1 , comprising less than 5×10 −14 endotoxin units per filamentous bacteriophage.

6 . The pharmaceutical composition of claim 1 , wherein the composition is a liquid composition.

7 . The pharmaceutical composition of claim 1 , having at least 4×10 17 filamentous bacteriophage.

8 . The pharmaceutical composition of claim 1 wherein the filamentous bacteriophage are M13.

9 . The pharmaceutical composition of claim 1 in a solid form.

10 . The pharmaceutical composition of claim 9 , formulated into tablets, granulates, nano-particles, nano-capsule micro-capsules, micro-tablets, pellets, or powders.

11 . The pharmaceutical composition of claim 1 formulated into a single dosage form.

12 . The pharmaceutical composition of claim 11 , wherein the single dosage form is contained in a vial.

13 . The pharmaceutical composition of claim 11 , wherein the single dosage form is contained in an infusion bag or pump reservoir.

14 . The pharmaceutical composition of claim 11 , wherein the single dosage form is contained in one or more tablets or capsules.

15 . The pharmaceutical composition of claim 1 , comprising an amount of endotoxin that when administered to a human provides less than 5.0 endotoxin units per kilogram body weight per dose.

16 . The pharmaceutical composition of claim 15 , comprising an amount of endotoxin that when administered to a human provides less than 0.2 endotoxin units per kilogram body weight per dose.

17 . A method of reducing the amount of amyloid plaque in a patient suffering from a plaque-forming disease, comprising the step of administering to the patient a pharmaceutical composition comprising filamentous bacteriophage; and a pharmaceutically acceptable carrier, wherein the composition comprises less than 1×10 −10 endotoxin units per filamentous bacteriophage.

18 . The method of claim 17 , wherein the filamentous bacteriophage is selected from wild-type filamentous bacteriophage or filamentous bacteriophage which does not display an antibody or a non-filamentous bacteriophage antigen on its surface.

19 . The method of claim 17 , wherein the plaque-forming disease is selected from Alzheimer's disease, SAA amyloidosis, hereditary Icelandic Syndrome, senility, multiple myeloma, Kuru, Creutzfeldt-Jakob Disease (CJD), Gerstmann-Straussler-Scheinker disease (GSS), fatal familial insomnia (FFI), scrapie, bovine spongiform encephalitis (BSE), Parkinson's Disease, Amyotrophic lateral sclerosis/parkinsonism-dementia complex, Argyrophilic grain dementia, Corticobasal degeneration, Dementia pugilistica, diffuse neurofibrillary tangles with calcification, Down's syndrome, Frontotemporal dementia with parkinsonism linked to chromosome 17, Hallervorden-Spatz disease, Myotonic dystrophy, Niemann-Pick disease type C, Non-Guamanian motor neuron disease with neurofibrillary tangles, Pick's disease, Postencephalitic parkinsonism, Progressive subcortical gliosis, Progressive supranuclear palsy, Subacute sclerosing panencephalitis, and Tangle only dementia.

20 . The method of claim 19 , wherein the plaque-forming disease is selected from early onset Alzheimer's disease, late onset Alzheimer's disease or pre-symptomatic Alzheimer's disease.